121659-86-7

Basic information

• Product Name: Methyl 4-(4'-fluorophenyl)-2-(cyclopropyl)-3-quinolinecarboxylate
• Synonyms: Methyl 2-cyclopropyl-4-(4-fluorophenyl）-3-quinolinecarboxylate;METHYL 4-(4''-FLUOROPHENYL)-2-(CYCLOPROPYL)-3-QUINOLINECARBOXYLATE;2-Cyclopropyl-4-(4-fluorophenyl)quinoline-3-carboxylic acid methyl ester;4-(4-Fluorophenyl)-2-cyclopropylquinoline-3-carboxylic acid methyl ester;2-Cyclopropyl-4-(4-fluorophenyl)-3-quinolinecarboxylic Acid Methyl Ester;Methyl 2-cyclopropyl-4-(4-fluorophenyl)-quinoline-3-carboxylate
• CAS NO: 121659-86-7
• Molecular Formula: C₂₀H₁₆FNO₂
• Molecular Weight: 321.34
• EINECS: 1806241-263-5
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Pitavastatin Calcium Intermediates
• Mol File: 121659-86-7.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 458.109 °C at 760 mmHg
• Flash Point: 230.856 °C
• Appearance: /
• Density: 1.274
• Storage Temp.: 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 3.43±0.50(Predicted)
• CAS DataBase Reference: Methyl 4-(4'-fluorophenyl)-2-(cyclopropyl)-3-quinolinecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(4'-fluorophenyl)-2-(cyclopropyl)-3-quinolinecarboxylate(121659-86-7)
• EPA Substance Registry System: Methyl 4-(4'-fluorophenyl)-2-(cyclopropyl)-3-quinolinecarboxylate(121659-86-7)

Safety Data

• Hazardous Substances Data: 121659-86-7(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

Uses

Pitavastatin intermediate.

Upstream product

• 1765-93-1 4-fluoroboronic acid 
• 462-06-6 fluorobenzene 
• 552-16-9 ortho-nitrobenzoic acid 
• 120303-62-0 (4-fluorophenyl)(2-nitrophenyl)methanone 
• 765-43-5 Cyclopropyl methyl ketone 
• 449181-32-2 4-Fluoro-2'-aminobenzophenone methansulfonic acid salt 
• 32249-35-7 methyl 3-cyclopropyl-3-oxopropanoate 
• 3800-06-4 2-amino-4'-fluorobenzophenone 

Downstream Products

• 154057-58-6 <2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl>methyltriphenylphosphonium bromide 
• 147526-32-7 pitavastatin calcium salt 
• 147526-32-7 pitavastatin 
• 574705-92-3 sodium (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]-3,5-dihydroxyhept-6-enoate 
• 147489-06-3 (4R,6S)-(E)-{6-[2-(2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl)-vinyl]-2,2-dimethyl-1,3-dioxan-4-yl}acetic acid tert-butyl ester 
• 586966-54-3 (3R,5S,6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-3,5-dihydroxy-6-heptenoic acid tert-butyl ester 
• 121660-37-5 2-cyclopropyl-4-(4-fluorophenyl)-3-formylquinoline 
• 172336-32-2 ethyl (E)-3,5-dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinyl]hept-6-enoate 
• 391681-95-1 2-cyclopropyl-3-(3-ethoxy-1-hydroxy-2-propenyl)-4-(4-fluorophenyl)quinoline 
• 172336-32-2 (±)-E-3,5-dihydroxy-7-[2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl]-6-heptenoic acid ethyl ester 
• 148901-69-3 (E)-7-[2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl]-5-hydroxy-3-oxohept-6-enic acid ethyl ester 
• 148901-68-2 (E)-3-[2-cyclopropyl-4-(4-fluoro-phenyl)-quinolin-3-yl]-propenal 
• 121660-11-5 2-cyclopropyl-4-(4-fluorophenyl)-3-(hydroxymethyl)quinoline 

Relevant articles and documents

Preparation method of intermediate of pitavastatin calcium

The invention relates to a preparation method of an intermediate 2-cyclopropyl-4-(4-fluorophenyl)-3-quinolinecarboxylate of pitavastatin calcium. The method comprises the following steps: with 2-aminobenzonitrile and 3-cyclopropyl-3-oxo-propionate as star

Process for Preparing Pitavastatin, Intermediates and Pharmaceuctically Acceptable Salts Thereof

Processes for preparing pravastatin, intermediates and pharmaceutically acceptable salts thereof are provided Crystalline forms of pravastatin, intermediates and pharmaceutically acceptable salts thereof are also disclosed.

Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors

A series of quinoline-based 3,5-dihydroxyheptenoic acid derivatives were synthesized from quinolinecarboxylic acid esters by homologation, aldol condensation with ethyl acetoacetate dianion, and reduction of 3-hydroxyketone to evaluate their ability to inhibit the enzyme HMG-CoA reductase in vitro. In agreement with previous literature, a strict structural requirement exists on the external ring, and 4-fluorophenyl is the most active in this system. For the central ring, substitution on positions 6, 7, and 8 of the central quinoline nucleus moderately affected the potency, whereas the alkyl side chain on the 2-position had a more pronounced influence on activity. Among the derivatives, NK-104 (pitavastatin calcium), which has a cyclopropyl group as the alkyl side chain, showed the greatest potency. We found that further modulation and improvement in potency at inhibiting HMG-CoA reductase was obtained by having the optimal substituents flanking the desmethylmevalonic acid portion, that is, 4-fluorophenyl and cyclopropyl, instead of the usual isopropyl group.